In 2018, Abbvie's rheumatoid arthritis drug Humira once again topped the list of best-selling drugs, according to a new analysis published in Nature.
Below is a breakdown of the 10 top-selling drugs globally:
1. Humira (AbbVie) $19.9 billion
2. Revlimid (Celgene) $9.7 billion
3. Keytruda (Merck & Co.) $7.2 billion
4. Herceptin (Roche) $7.1 billion
5. Avastin (Roche) $7.0 billion
6. Rituxan (Roche) $6.9 billion
7. Opdivo (Bristol-Myers Squibb) $6.7 billion
8. Eliquis (Bristol-Myers Squibb) $6.4 billion
9. Prevnar 13 (Pfizer) $5.8 billion
10. Stelara (Johnson & Johnson) $5.2 billion